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Abstract
Massively parallel sequencing of DNA molecules in the plasma of pregnant women has been shown to allow accurate and
noninvasive prenatal detection of fetal trisomy 21. However, whether the sequencing approach is as accurate for the
noninvasive prenatal diagnosis of trisomy 13 and 18 is unclear due to the lack of data from a large sample set. We studied
392 pregnancies, among which 25 involved a trisomy 13 fetus and 37 involved a trisomy 18 fetus, by massively parallel
sequencing. By using our previously reported standard z-score approach, we demonstrated that this approach could
identify 36.0% and 73.0% of trisomy 13 and 18 at specificities of 92.4% and 97.2%, respectively. We aimed to improve the
detection of trisomy 13 and 18 by using a non-repeat-masked reference human genome instead of a repeat-masked one to
increase the number of aligned sequence reads for each sample. We then applied a bioinformatics approach to correct GC
content bias in the sequencing data. With these measures, we detected all (25 out of 25) trisomy 13 fetuses at a specificity of
98.9% (261 out of 264 non-trisomy 13 cases), and 91.9% (34 out of 37) of the trisomy 18 fetuses at 98.0% specificity (247 out
of 252 non-trisomy 18 cases). These data indicate that with appropriate bioinformatics analysis, noninvasive prenatal
diagnosis of trisomy 13 and trisomy 18 by maternal plasma DNA sequencing is achievable.
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Introduction
Trisomy 13 (Patau syndrome) and trisomy 18 (Edwards
syndrome) are the most clinically important autosomal trisomies
besides trisomy 21. Trisomy 13 occurs in about 1 out of every
10,000 newborns and the incidence of trisomy 18 is estimated to
be 1 in 6,000 live births [1].
Detection of such fetal chromosomal aberrations is an
important indication for prenatal diagnosis. Conventional prenatal
diagnostic methods, such as sampling of fetal genetic materials by
amniocentesis or chorionic villus sampling, are invasive, and carry
potential risks to the fetus [2]. Besides these invasive approaches,
noninvasive screening approaches by ultrasound scanning and
maternal serum markers are useful for identifying high-risk cases,
but have limited sensitivity and specificity. For example, the
detection rate of first-trimester combined screening is 77%–86%
and the false positive rate is 3.2%–5.6% [3]. These approaches
measure epiphenomena associated with the trisomies, rather than
directly detecting the core abnormality involving chromosomal
dosage [3,4].
Cell-free fetal DNA has been shown to be present in the plasma
of pregnant women [5], and has opened up new possibilities for
noninvasive prenatal diagnosis [6]. Tests based on circulating fetal
DNA have been used clinically for the prenatal management of
sex-linked disorders and rhesus D incompatibility [7–9]. Recently,
strategies have also been developed for the noninvasive diagnosis
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plasma, including the detection of fetal DNA methylation
signatures and mRNA markers in maternal plasma [10–15].
In addition, when a woman is pregnant with a trisomic fetus,
there should be an increased proportion, i.e. over representation,
of fetal-derived DNA molecules from the extra chromosome in
her plasma when compared to a pregnancy with a euploid fetus.
With the availability of massively parallel sequencing (MPS)
technologies which sequence DNA molecules in a high
throughput manner, the genomic identities and quantities of
millions of DNA molecules in biological samples could be
determined. It has been shown that sequencing of maternal
plasma DNA can be applied to the noninvasive detection of fetal
trisomy 21 [16–19]. Essentially, maternal plasma DNA molecules
are sequenced, and the chromosomal origin of each sequenced
molecule is identified by comparing to a reference human
genome sequence. The number of molecules derived from
chromosome 21 (chr21) as a proportion of all sequenced
molecules has been shown to be elevated in trisomy 21
pregnancies when compared with euploid ones. Our group has
demonstrated that detection of fetal trisomy 21 could be achieved
using two different MPS platforms, namely the sequencing-by-
synthesis (SBS) platform [16] and the sequencing-by-ligation
(SBL) platform [17]. Two recent large scale studies on trisomy 21
detection based on SBS platform both showed a 100% sensitivity
and 97.9% to 99.7% specificity [19,20].
Theoretically, if there were no analytical or biological bias of
M P S ,i tw o u l db ee x p e c t e dt h a tt h em o l e c u l e sf r o mt h ew h o l e
genome could be sequenced uniformly by the procedure.
However, it has been reported that molecules from different
regions of a genome may not be uniformly sequenced by MPS.
The guanine and cytosine (GC) content of the sequenced nucleic
acids has been reported to contribute to the non-uniformity
[21,22]. Fan et al. and our group found that the patterns of non-
uniform representation of each chromosome were different
when maternal plasma DNA was sequenced with the use of
different MPS platforms [17,18]. These data suggest that the
non-uniform representation of each chromosome is more likely
to be due to sequencing or alignment bias than biological
reasons [17,21]. Furthermore, in our previous study, we have
highlighted that chr13 and chr18 have relatively lower average
GC content than chr21 which has a modest average GC content
[16]. In addition, we have previously shown that the
measurement of the genomic representations of chr13 and
chr18 is less precise than that for chr21 based on both the SBS
and SBL platforms [16,17]. The variance of measuring the
genomic representations of chr13 and chr18, as indicated by the
coefficient of variation (CV), are 5.8 times and 2.4 times,
respectively, greater than that of chr21 on the SBS platform
[16]. Similar results were also observed on the SBL platform on
which the variance of measuring the genomic representations of
chr13 and chr18 are 5.7 times and 1.8 times, respectively,
greater than that of chr21 [17]. These observations have led us
to hypothesize that noninvasive prenatal diagnosis of trisomy 13
and trisomy 18 by MPS would likely be less accurate than for
trisomy 21 [17]. As the variance in the GC content of the
sequenced molecules is a contributor to the issue, quantitative
correction to minimize such an effect on the measurement of the
genomic representations of chr13 and chr18 might allow
accurate diagnosis of trisomy 13 and trisomy 18.
To this end, here we assessed the prenatal diagnostic
performance by MPS of maternal plasma DNA on a cohort of
392 pregnancies of whom 25 involved trisomy 13 fetuses and 37
involved trisomy 18 fetuses.
Methods
Ethics Statement
Approvals were obtained from the institutional review boards of
each recruitment site: Joint Chinese University of Hong Kong-
New Territories East Cluster Clinical Research Ethics Committee,
Joint Institutional Review Board of the University of Hong Kong-
Hospital Authority Hong Kong West Cluster, Clinical and
Research Ethics Committees of the Hospital Authority in the
Kowloon Central/Kowloon East, Kowloon West, Hong Kong
East, New Territories West Clusters, King’s College Hospital
Ethics Committee and Ethics Committee of the VU University
Medical Center. All participants gave informed written consent.
Study design, setting and population
252 participants were recruited prospectively from Hong Kong,
the Netherlands and UK. 140 archived maternal plasma samples
from pregnancies with and without trisomy 13, 18 or 21, matched
for gestational ages were also retrieved from the participating sites
in the Netherlands and UK. Samples that passed the inclusion
criteria as described in our previous investigation on the prenatal
diagnosis of trisomy 21 [20] were used in this study. Only singleton
pregnancies with clinical indications for amniocentesis or CVS
were recruited and samples with full karyotypes were included.
A total of 392 cases were analyzed, including 25 cases each
involving a trisomy 13 fetus, 37 cases each involving a trisomy 18
fetus and 86 cases each involving a trisomy 21 fetus (Figure 1). 314
of the cases were those analyzed using 2-plex sequencing (see
below) in a recent study on the noninvasive diagnosis of trisomy 21
[20]. Another 30 cases were from those analyzed using 8-plex
sequencing by Chiu et al [20], but were re-sequenced in this study
using 2-plex sequencing. The remaining 48 cases were newly
recruited and sequenced in this study. 91 cases in the previously
recruited cases and 12 cases in the newly recruited cases, which
were from women pregnant with a euploid fetus, were used as
normal controls.
Maternal plasma DNA sequencing
Plasma samples from participating pregnant women were
processed as previously described [16,20]. Briefly, five to ten
milliliters of peripheral venous blood was collected from each
participating pregnant woman in ethylenediaminetetraacetic acid
(EDTA)-containing tubes. The blood samples were first centri-
fuged at 1,600 g for 10 min at 4uC so as to separate the plasma
from the peripheral blood cells. The plasma portion was carefully
transferred to plain polypropylene tubes and then subjected to
Figure 1. Recruitment of samples.
doi:10.1371/journal.pone.0021791.g001
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remaining cells [23]. Plasma DNA from 2 to 4.8 milliliters of
maternal plasma was extracted by using the QIAamp DSP DNA
blood mini kit (Qiagen, Hilden, Germany) following the blood and
body fluid protocol.
The DNA library for the extracted plasma DNA was
constructed using the Genomic DNA Library Preparation Kit
and Multiplexing Sample Preparation Oligonucleotide kit (Illu-
mina) mostly according to manufacturer’s instructions. Since
plasma DNA molecules are short fragments in nature [24]; hence,
the steps of fragmentation and size selection by gel electrophoresis
were omitted. Multiplexing was achieved by introducing a 6-bp
index barcode to the adapter-ligated DNA of each plasma sample
through a triple-primer PCR amplification.
Indexed DNA libraries were sequenced using the 2-plex strategy
[20]. 2-plex multiplexing allows two plasma samples to be
sequenced in each lane by using different short index sequences
(6 bp) for different samples. The index sequences were randomly
assigned tothesequencing samples and had atleastthree-nucleotide
differences between each other. A total of 16 specimens could be
sequenced in each run. DNA clusters were generated using an
Illumina cluster station according to manufacturer’s instructions.
We sequenced 36 basepairs (bp) from one end of each plasma DNA
molecule. An additional 7 cycles of sequencing were performed to
decode the index sequence on each sequenced plasma DNA
molecule. The sequencing was performed on the Genome Analyzer
IIx (Illumina) using the Sequencing Kit V3 (Illumina).
Samples from women pregnant with male euploid fetuses were
used as controls for trisomy detection. Four control samples were
sequenced in each sequencing run. Thus, in each 2-plex
sequencing run, the remaining 12 samples (either trisomy or
euploid) were test samples. Samples from women pregnant with
trisomic fetuses were identified by comparing the test samples with
control samples within each sequencing run by a specific statistical
approach. Two statistical approaches have been developed for the
diagnosis of trisomy 13 and trisomy 18. One is our previously
reported approach (named the standard z-score approach) which
was originally designed for trisomy 21 diagnosis [16]. The other
was based on z-score calculation but with an additional GC
correction step (named the z-score approach with GC correction).
Diagnostic performance of these two approaches was assessed by
comparing with the results of full karyotyping of the amniotic fluid
or chorionic villus samples.
Sequencing data analysis
The 36-bp read from one end of each sequenced plasma DNA
molecule was first mapped to the repeat-masked reference human
genome (NCBI Build 36 version 48) using the Short Oligonucleotide
Alignment Program 2 (SOAP2) [25] with no mismatches allowed.
Then, in order to increase the number of aligned reads for each
sample, we also mapped the reads to the non-repeat-masked
reference human genome (Hg18 NCBI.36). We only used the
‘‘unique perfectly aligned reads’’, defined as reads that could be
mapped to only one location without any mismatch in the reference
human genome, for further analysis. Due to the 2-plex sequencing
strategy, the reads in each lane were then sorted back to the
corresponding samples according to the index DNA sequence
information with one mismatch allowed in the index DNA sequences.
Detection of trisomy 13 and trisomy 18
We counted the number of aligned reads for each chromosome.
The genomic representations of chr13 and chr18 are defined as
the percentages of the aligned reads originated from chr13 and
chr18, respectively, among the total reads sequenced from a
sample. A maternal plasma sample from a pregnancy with a
trisomy 13/18 fetus is expected to have a higher genomic
representation of chr13/18 compared with a set of reference
samples (samples from women pregnant with euploid fetuses). In
order to quantitatively measure this overrepresentation for each
tested sample, for the standard z-score approach, the z-score for
the chromosome of interest (chr13/18) was calculated by the
following equation:
z{score test sample ~ GR test sample{ GR mean reference samples

=SD reference samples
ð1Þ
where GR test sample is the genomic representation of the
chromosome of interest in the test sample; GR mean reference samples
is the mean of the genomic representations of the chromosome of
interest for all reference samples; and SD reference samples is the
standard deviation of the genomic representations of the
chromosome of interest for the reference samples.
For the z-score approach with GC correction, instead of using
read counts to directly calculate the genomic representations of the
chromosomes of interest, a GC-corrected read count was used to
calculate the genomic representations with an aim to eliminate the
effect of the GC bias on the sequenced read counts. For each
sample, all chromosomes were first bioinformatically divided into
segments of the same size, called bins. In preliminary analyses, we
tested bin sizes of 50 kb, 100 kb, 500 kb and 1000 kb. We found
that the CVs for measuring chr13 and chr18 in maternal plasma
did not vary significantly using these bin sizes. Thus, we chose
50 kb as the bin size for all subsequent analyses. The number of
sequenced reads and GC content in each bin (rounded to 0.1%)
were determined. We filtered bins without any reads and bins with
‘N’ in the sequences. Then, locally weighted scatterplot smoothing
(LOESS) regression was applied to fit the number of sequenced
reads in each bin against the GC content of the corresponding bin
in order to calculate the LOESS fit predicted value (P) [22]. Using
the regression function and the GC content of each bin, we
obtained the LOESS fit predicted value for each bin. The GC
corrected read counts (RCGC) of each bin were calculated from the
raw read counts (RCraw) with the correction factor (F). The latter
was derived from the median counts of all the bins (M) and the
LOESS fit predicted value by the following equations:
F ~ M=P ð2Þ
RCGC~ RCraw|F ð3Þ
After GC correction, the z-score statistic was calculated by using
the genomic representations derived from the GC-corrected read
counts of chr13/18 with equation 1.
For both approaches, a z-score value greater than 3,
representing a genomic representation greater than that of the
99.9
th percentile of the reference set for a one-tailed distribution,
was used as the cut-off to determine if overrepresentation of
chr13/18 plasma DNA molecules and hence fetal trisomy 13/18
was present.
Statistical analysis
We reported the diagnostic sensitivity and specificity values of
the standard z-score approach and the z-score approach with GC
correction, using the z-score value of 3 as the cutoff. LOESS
Noninvasive Diagnosis of Trisomies 18 and 13
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project.org/) with default parameters. Spearman correlation
coefficient analysis and z-score calculation were also performed
by R.
Results
Study participants
392 pregnancies were studied (Figure 1). Amongst these, 243
had euploid fetuses. 103 of these samples were used as reference
control samples for z-score calculation. Amongst these, 90 and 13
euploid cases were used as reference controls in one and two flow
cells, respectively. To study the detection of the two trisomies, 25
trisomy 13 cases were compared with 264 non-trisomy 13 cases
(consisting of 140 euploid cases not used as reference controls, 86
trisomy 21 cases, 1 sex chromosome mosaic case and 37 trisomy
18 cases). Similarly, 37 trisomy 18 cases were compared with 252
non-trisomy 18 cases (consisting of 140 euploid cases not used as
reference controls, 86 trisomy 21 cases, 1 sex chromosome mosaic
case and 25 trisomy 13 cases).
Diagnostic performance of the standard z-score
approach
We first tested our previously reported standard z-score
approach for trisomy 13 and trisomy 18 detection. We first
aligned all the reads to the repeat-masked reference human
genome as we did in our previous study [16,20]. After alignment,
we obtained a mean of 2.4 million (SD 508,842) unique perfectly
aligned reads per maternal plasma sample. The average per base
coverage per genome is 0.028 (SD 0.006). The diagnostic
performance of the standard z-score approach for detecting fetal
trisomy 13 and trisomy 18 is shown in Tables 1, 2 and 3. The z-
scores of chr13 and chr18 are shown in Figures 2A and 2B. Using
a chr13/18 z-score value of 3 as the cutoff, only 9 of the 25 trisomy
13 cases were detected. In addition, 244 of the 264 non-trisomy 13
cases were classified correctly. In other words, the sensitivity and
specificity for detecting trisomy 13 were 36.0% and 92.4%,
respectively. For the detection of the trisomy 18 cases, 27 of 37
trisomy 18 cases and 245 of 252 non-trisomy 18 cases were
classified correctly, giving a sensitivity and specificity of 73.0% and
97.2%, respectively.
The diagnostic performances for trisomy 13 and 18 detection
were worse than that for trisomy 21 which was 100% sensitive and
97.9% specific [20]. We therefore investigated a number of
bioinformatics approaches to try to improve the classification
accuracies for trisomy 13 and 18. As the statistical power of the
molecular counting approach used in the current study increased
with the number of counted molecules [26], we attempted to
increase the number of aligned reads by using the non-repeat-
masked reference human genome for alignment. Consequently,
we obtained a mean of 4.6 million (SD 964,094) unique perfectly
aligned reads per maternal plasma sample. The average per base
coverage per genome is 0.053 (SD 0.011). The diagnostic
performances of the standard z-score approach for detecting fetal
trisomy 13 and trisomy 18 using these increased aligned read
counts are shown in Tables 1, 2 and 3. The z-scores of chr13 and
chr18 are shown in Figures 2A and 2B. For trisomy 13 detection,
11 of 25 trisomy 13 cases and 247 of 264 non-trisomy 13 cases
were identified correctly, corresponding to improved sensitivity
and specificity of 44.0% and 93.6%, respectively. For trisomy 18,
31 of 37 trisomy 18 cases and 247 of 252 non-trisomy 18 cases
were identified correctly, corresponding to sensitivity and
specificity of 83.8% and 98.0%, respectively.
Diagnostic performance of the z-score approach with GC
correction
Although the detection accuracies of trisomy 13 and trisomy 18
were improved by using the non-repeat masked reference genome
Table 1. Actual and predicted outcome of maternal plasma DNA sequencing for fetal trisomy 13 detection.
Standard z-score approach Standard z-score approach Z-score approach with GC correction
(repeat-masked genome) (non-repeat-masked genome) (non-repeat-masked genome)
Predicted Predicted Predicted
T13 Non-T13 T13 Non-T13 T13 Non-T13
Actual T13 9 16 11 14 25 0
Non-T13 20 244 17 247 3 261
T13: trisomy 13. chr13 z-score .3 was used as the diagnostic cut-off.
doi:10.1371/journal.pone.0021791.t001
Table 2. Actual and predicted outcome of maternal plasma DNA sequencing for fetal trisomy 18 detection.
Standard z-score approach Standard z-score approach Z-score approach with GC correction
(repeat-masked genome) (non-repeat-masked genome) (non-repeat-masked genome)
Predicted Predicted Predicted
T18 Non-T18 T18 Non-T18 T18 Non-T18
Actual T18 27 10 31 6 34 3
Non-T18 7 245 5 247 5 247
T18, trisomy 18. chr18 z-score .3 was used as the diagnostic cut-off.
doi:10.1371/journal.pone.0021791.t002
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improvement. We thus attempted to further improve the
classification accuracies for trisomy 13 and trisomy 18 by applying
a GC correction algorithm. For the z-score approach with GC
correction, when using the same diagnostic z-score value of 3, all
the trisomy 13 cases (25 out of 25) were successfully identified,
while 261 out of 264 non-trisomy 13 cases were correctly classified
(Figure 2A and Table 1). The sensitivity and specificity of this
approach were thus 100% and 98.9%, respectively (Table 3). For
trisomy 18, 34 out of 37 trisomy 18 cases and 247 out of 252 non-
trisomy 18 cases were correctly identified (Figure 2B and Table 2),
corresponding to sensitivity and specificity of 91.9% and 98.0%,
respectively (Table 3).
GC correction improved the precision for measuring
genomic representations of chr13 and chr18 in plasma
The improved diagnostic performance of the z-score approach
with GC correction compared with the standard z-score approach
is likely to be due to amelioration of the sequencing GC bias and
the more precise measurement of the genomic representations of
chr13 and chr18 (the percentage of read counts from chr13 and
chr18 over the total read count) in maternal plasma.
As there is a strong positive correlation between read counts and
the average GC content of all bins (average Spearman correlation
coefficient for all the samples =0.56, SD =0.13, all p value
,1.0610
210 for all samples except one), the difference in GC
content between different chromosomes would likely lead to
quantitative biases in the genomic representations of fragments
from different chromosomes and hence affect the precision of their
measurement in plasma [17].
Thus, we calculated the CV for measuring the genomic
representation of each autosome among the euploid control
samples within each sequencing run. As shown in Figure 3, the
autosomes with high or low GC content tend to exhibit a higher
variance than autosomes with average GC content. The average
CVs for measuring the genomic representations of chromosomes
13 and 18 based on our previous analysis strategy (repeat-masked
genome without GC correction) were 1.5% and 0.86%, respec-
Table 3. Diagnostic performance of maternal plasma DNA sequencing for fetal trisomy 13 and 18 detection.
Standard z-score approach Standard z-score approach Z-score approach with GC correction
(repeat-masked genome) (non-repeat-masked genome) (non-repeat-masked genome)
T13 T18 T13 T18 T13 T18
Sensitivity: 36.0% 73.0% 44.0% 83.8% 100.0% 91.9%
Specificity: 92.4% 97.2% 93.6% 98.0% 98.9% 98.0%
PPV: 31.0% 79.4% 39.3% 86.1% 89.3% 87.2%
NPV: 93.8% 96.1% 94.6% 97.6% 100.0% 98.8%
PPV: positive predictive value, NPV: negative predictive value, T13: trisomy 13, T18, trisomy 18. chr13 or 18 z-score .3 was used as the diagnostic cut-off.
doi:10.1371/journal.pone.0021791.t003
Figure 2. Z-scores of chromosome 13 and 18 determined by
the standard z-score approach and the z-score approach with
GC correction. Z-scores of (A) chromosome 13 and (B) chromosome
18 determined by the standard z-score approach with alignment
against the repeat-masked or non-repeat-masked reference genomes
and the z-score approach with GC correction are shown. Horizontal
dashed lines indicate the z-score cut off value of 3. T13, trisomy 13. T18,
trisomy 18.
doi:10.1371/journal.pone.0021791.g002
Figure 3. Precision before and after GC correction for the
autosomes. Coefficient of variation (CV) for each chromosome was
calculated based on the control euploid cases before GC correction
with alignment against the repeat-masked or non-repeat-masked
reference genomes and after GC correction with alignment against
the non-repeat-masked reference genome. Chromosomes are ordered
from left to right in increasing GC contents. GC content of each
chromosome is shown in the brackets. 95% confidence interval was
shown in error bars.
doi:10.1371/journal.pone.0021791.g003
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the CVs for chromosomes 13 and 18 were 1.1% and 0.66%,
respectively. After further applying GC correction, the CVs for
measuring the genomic representations of chromosomes 13 and 18
decreased to 0.31% and 0.33%, representing overall reductions of
79.7% and 61.2%, respectively. These results indicate that our
analysis strategy has markedly improved the precision of
quantification of chromosome 13 and chromosome 18, and would
therefore result in greater differentiation in the z-score values
between the respective trisomy and non-trisomy cases.
Discussion
This study reports a large series of trisomy 13 and trisomy 18
cases assessed for noninvasive prenatal diagnosis by MPS. We
showed that the use of the non-repeat-masked genome as
reference and the GC correction approach improved the accuracy
of trisomy 13 and trisomy 18 diagnosis based on maternal plasma
DNA sequencing.
In essence, accurate diagnosis of trisomy 13 and trisomy 18 could
be achieved by having more aligned reads in general. Besides using
the non-repeat-masked genome as the alignment reference, another
way to increase the number of aligned reads is to perform deeper
sequencing. However, the sequencing cost would also increase
along with the more sequencing reads. Therefore, increasing the
numberofalignedreads ina bioinformatics way, asdescribedinthis
study, is relatively more cost-effective.
The sequencing read length is a potential factor which could
alter the proportion of the aligned reads. In this study, we used 36-
bp sequenced reads for our application since they were long
enough to be aligned to the reference genome and the sequencing
time required was short enough to meet the required turnaround
time for a diagnostic test. It has been shown that reads with 35-bp
length can be uniquely aligned to the human genome at an
alignment rate of 85.4% [27]. Although longer reads may
contribute to slightly higher alignment [27], the tradeoff is a
longer sequencing time. On the other hand, paired-end reads may
improve the alignment accuracy but also requires longer
sequencing time. Other factors which might be usefully investi-
gated in future work would include improvements in plasma DNA
isolation method and technologies for enriching fetal DNA based
on size selection [24,28].
We observed that the improvement for trisomy 13 was more
marked than that for trisomy 18, probably because of the more
significant deviation in the GC content for chr13 (around 38.5%)
when compared with a chromosome with average GC content
(e.g. chr21, with GC content of 40.9%). In comparison, chr18 has
a GC content (39.8%) much closer to that of chr21.
Besides the GC correction method described in this study, we
have also started exploring another approach to reduce the GC
bias by assembling an ‘artificial reference genome’ with genomic
regions selected for specific GC content characteristics. Future
work would shed light with regard to the relative merits of these
approaches.
Fan et al. also reported a study on the diagnosis of trisomy 13
and trisomy 18 by maternal plasma DNA sequencing [29].
However, compared with our study involving 25 samples from
women pregnant with trisomy 13 fetuses and 37 samples from
pregnant women with trisomy 18 fetuses, their test sample size is
small which included only 2 trisomy 18 cases and 1 trisomy 13
case. With such a small sample size, it was difficult to conclusively
ascertain the diagnostic accuracies of their procedures. Further-
more, the samples in their study were collected soon after
amniocentesis or chorionic villus sampling, which might result in
an increase of fetal DNA concentration in maternal circulation
[30]. Conversely, our much larger study was based on samples
collected before amniocentesis or chorionic villus sampling.
In conclusion, maternal plasma DNA sequencing with statistical
correction can accurately detect fetal trisomy 13 and trisomy 18
with high detection rate and low false positive rate. Currently, the
laboratory cost of our approach including the cost for sequencing
reagents and labor is around USD 1000 per case. However, the
sequencing cost is expected to rapidly decrease in the future.
Furthermore, we have also recently shown that maternal plasma
DNA sequencing can also allow one to construct a genome-wide
genetic and mutational map of the fetus. Thus, we believe that
plasma DNA sequencing would play an increasingly important
part of future obstetrics care.
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